Importer of Controlled Substances; Notice of Registration; Cody Laboratories, Inc., 60143-60144 [2012-24195]
Download as PDF
<![CDATA[
60143
Federal Register / Vol. 77, No. 191 / Tuesday, October 2, 2012 / Notices
facilities that are owned or operated by
the defendant in Maricopa County,
Arizona. The Consent Decree resolves
the civil claims alleged in the complaint
and in the Finding and Notice of
Violation issued to the defendant in
September 2010.
The publication of this notice opens
a period for public comment on the
Consent Decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States v. CEMEX Construction
Materials South, LLC, D.J. Ref. No. 90–
5–2–1–10139. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit comments:
Send them to:
By email ....................
pubcomment-ees.
enrd@usdoj.gov.
Assistant Attorney
General, U.S.
DOJ—ENRD, P.O.
Box 7611, Washington, DC 20044–
7611.
By mail ......................
During the public comment period,
the Consent Decree may be examined
and downloaded at this Justice
Department Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. We will provide
a paper copy of the Consent Decree
upon written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ–ENRD, P.O. Box 7611,
Washington, DC 20044–7611.
Please enclose a check or money order
for $10.25 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2012–24162 Filed 10–1–12; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Fisher Clinical
Services, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on July 18, 2012, Fisher Clinical
Services, Inc., 7554 Schantz Road,
Allentown, Pennsylvania 18106, made
application by renewal to the Drug
VerDate Mar<15>2010
15:04 Oct 01, 2012
Jkt 229001
Enforcement Administration (DEA) for
registration as an importer of
Noroxymorphone (9668), a basic class of
controlled substance in schedule II.
The company plans to import the
listed substance for analytical research
and clinical trials.
The import of the above listed basic
class of controlled substance would be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
FDA approved or non-approved dosage
form for commercial distribution in the
United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedules I or II, which fall
under the authority of section
1002(a)(2)(B) of the Act [21 U.S.C.
952(a)(2)(B)] may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 1, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: September 20, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–24191 Filed 10–1–12; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Cody
Laboratories, Inc.
By Notice dated July 17, 2012, and
published in the Federal Register on
July 26, 2012, 77 FR 43861, Cody
Laboratories, Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414–9321,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug
Opium, raw (9600) .......................
Concentrate Poppy Straw (9670)
Tapentadol (9780) ........................
Schedule
II
II
II
The company plans to import narcotic
raw materials for manufacturing and
further distribution to its customers.
The company is registered with DEA
as a manufacturer of several controlled
substances that are manufactured from
opium raw, and poppy straw
concentrate.
The company plans to import an
intermediate form of Tapentadol (9780)
to bulk manufacture Tapentadol for
distribution to its customers.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate, 72 FR 3417
(2007). Regarding Tapentadol, no
comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Cody Laboratories, Inc., to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971.
DEA has investigated Cody
Laboratories, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
E:\FR\FM\02OCN1.SGM
02OCN1
60144
Federal Register / Vol. 77, No. 191 / Tuesday, October 2, 2012 / Notices
Dated: September 25, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–24195 Filed 10–1–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; United States
Pharmacopeial Convention
By Notice dated July 2, 2012, and
published in the Federal Register on
July 11, 2012, 77 FR 40911, United
States Pharmacopeial Convention,
12601 Twinbrook Parkway, Rockville,
Maryland 20852, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Methaqualone (2565) ...................
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
4-Methyl-2,5dimethoxyamphetamine (7395).
3,4-Methylenedioxyamphetamine
(7400).
Codeine-N-oxide (9053) ...............
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Phenmetrazine (1631) ..................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Phencyclidine (7471) ....................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Phenylacetone (8501) ..................
Alphaprodine (9010) .....................
Anileridine (9020) .........................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
VerDate Mar<15>2010
15:04 Oct 01, 2012
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 229001
The company plans to import
reference standards for sale to
researchers and analytical labs.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
United States Pharmacopeial
Convention to import the basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971.
DEA has investigated United States
Pharmacopeial Convention to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection,
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: September 20, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–24192 Filed 10–1–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Chemic Laboratories, Inc.
Pursuant to 1301.33(a), Title 21 of the
Code of Federal Regulations (CFR), this
is notice that on July 26, 2012, Chemic
Laboratories, Inc., 480 Neponset Street,
Building 7, Canton, Massachusetts
02021, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
small quantities of the above listed
controlled substance for distribution to
its customers for the purpose of
research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
PO 00000
Frm 00044
Fmt 4703
Sfmt 9990
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 3, 2012.
Dated: September 25, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–24182 Filed 10–1–12; 8:45 am]
BILLING CODE 4410–09–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Morton Grove Pharmaceuticals
Pursuant to 1301.33(a), Title 21 of the
Code of Federal Regulations (CFR), this
is notice that on July 12, 2012, Morton
Grove Pharmaceuticals, 6451 Main
Street, Morton Grove, Illinois 60053–
2633, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 3, 2012.
Dated: September 25, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–24184 Filed 10–1–12; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 77, Number 191 (Tuesday, October 2, 2012)]
[Notices]
[Pages 60143-60144]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24195]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration; Cody
Laboratories, Inc.
By Notice dated July 17, 2012, and published in the Federal
Register on July 26, 2012, 77 FR 43861, Cody Laboratories, Inc., 601
Yellowstone Avenue, Cody, Wyoming 82414-9321, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Opium, raw (9600).......................... II
Concentrate Poppy Straw (9670)............. II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import narcotic raw materials for
manufacturing and further distribution to its customers.
The company is registered with DEA as a manufacturer of several
controlled substances that are manufactured from opium raw, and poppy
straw concentrate.
The company plans to import an intermediate form of Tapentadol
(9780) to bulk manufacture Tapentadol for distribution to its
customers.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate, 72 FR 3417 (2007). Regarding
Tapentadol, no comments or objections have been received. DEA has
considered the factors in 21 U.S.C. 823(a) and 952(a) and determined
that the registration of Cody Laboratories, Inc., to import the basic
classes of controlled substances is consistent with the public interest
and with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971.
DEA has investigated Cody Laboratories, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic classes of controlled
substances listed.
[[Page 60144]]
Dated: September 25, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-24195 Filed 10-1-12; 8:45 am]
BILLING CODE 4410-09-P
